益气养阴汤联合厄洛替尼治疗气阴两虚型中晚期肺腺癌疗效及对患者中医症候和毒副反应的影响

Efficacy of Using Yiqi Yangyin Decoction Combined with Erlotinib in the Treatment of Qi-Yin Deficiency Type Advanced Lung Adenocarcinoma and its Inflence on Traditional Chinese Medicine Symptoms and Toxic and Side Effects

目的:观察益气养阴汤联合厄洛替尼治疗气阴两虚型中晚期肺腺癌疗效,及对患者中医症候和毒副反应的影响。方法:回顾性分析2016年6月-2019年6月于我院使用益气养阴汤+厄洛替尼治疗的中晚期肺腺癌(气阴两虚型)患者(研究组,n=52)与使用厄洛替尼治疗的中晚期肺腺癌(气阴两虚型)患者(对照组,n=52)的临床资料。对比两组患者治疗3个月后短期临床疗效,治疗前、治疗3个月后中医证候积分、肿瘤标记物[癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)]、生活质量(QLQ-C30评分)差异,并记录治疗期间毒副反应发生情况。结果:治疗3个月后,研究组总有效率为44.23%,显著高于对照组25.00%(P<0.05)。治疗3个月后,两组患者中医证候积分、CEA、CA125、CYFRA21-1水平较治疗前显著降低而QLQ-C30评分显著上升(P<0.05),且研究组患者上述指标与同期对照组对比差异显著(P<0.05)。治疗期间,研究组毒副反应发生率显著低于对照组(P<0.05)。结论:应用益气养阴汤联合厄洛替尼治疗气阴两虚型中晚期肺腺癌效果显著,可有效改善患者中医证候,调节患者体内肿瘤标记物,提升患者生活质量,降低毒副反应,有较好的应用价值。

Objective: To explore the efficacy of using Yiqi Yangyin Decoction combined with Erlotinib in the treatment of Qi-Yin deficiency type advanced lung adenocarcinoma, and its effects on TCM symptoms and toxic and side effects. Methods: Retrospective analysis was performed on clinical data of patients with Qi-Yin deficiency type advanced lung adenocarcinoma treated with Yiqi Yangyin Decoction + Erlotinib(study group, n=52) and patients with Qi-Yin deficiency type advanced lung adenocarcinoma of treated by Erlotinib(controlled group, n=52) in our hospital from January 2016 to June 2018. The short-term clinical efficacy after 3 months of treatment, and TCM syndromes scores, tumor markers [carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment(CYFRA21~1)] and quality of life(QLQ-C30 score) before treatment and after 3 months of treatment were compared between the two groups, and the occurrence of toxic and side effects were recorded during treatment. Results: After 3 months of treatment, the total effective rate in the study group was significantly higher than that in the controlled group(44.23% vs 25.00%)(P<0.05). After 3 months of treatment, the TCM syndromes scores and levels of CEA,CA125 and CYFRA21~1 in the two groups were significantly decreased compared with those before treatment while the QLQ-C30 score was significantly increased(P<0.05),and the above indicators in the study group were significantly different from those in the controlled group at the same period(P<0.05). During treatment, the incidence rate of toxic and side effects in the study group was significantly lower than that in the controlled group(P<0.05). Conclusion: Yiqi Yangyin Decoction combined with Erlotinib has significant effects in the treatment of Qi-Yin deficiency type advanced lung adenocarcinoma, and it can effectively improve the TCM syndromes, regulate the body tumor markers, improve the quality of life, and reduce toxic and side effects, with good application value.